via Johns Hopkins University School of Medicine
Johns Hopkins Medicine researchers have developed a color-coded test that quickly signals whether newly developed nanoparticles — ultra small compartments designed to ferry medicines, vaccines and other therapies — deliver their cargo into target cells.
Historically, nanoparticles have a very low delivery rate to the cytosol, the inside compartment of cells, releasing only about 1%–2% of their contents. The new testing tool, engineered specifically to test nanoparticles, could advance the search for next-generation biological medicines. The technology builds upon nanoparticles currently used against cancer and eye disease, and in vaccines for viruses including SARS-CoV-2, the virus that causes COVID-19.
The researchers report details of the tool, tested in mouse cells grown in the laboratory and in living mice, in the Jan. 5 issue of Science Advances.
“Many of the current assessment tools for nanoparticles only test whether a nanoparticle reaches a cell, not if the therapy can successfully escape the degradative environment of the endosome to reach inside the cytosol of the cell, which is where the medicine needs to be located for performance,” says Jordan Green, Ph.D., professor of biomedical engineering at the Johns Hopkins University School of Medicine. The new tool was created to track location and nanoparticle release, he said.
Previous research has estimated that only about 1%–2% of nanoparticles “eaten” by cells are able to escape the cellular compartments that trap them to avoid being digested or “spit back out.” In addition to the properties of its cargo, a nanoparticle’s chemical properties determine whether it is accepted by a cell and able to evade its cellular defenses.
To surmount such obstacles to final delivery, Green and his team designed a screening tool that assesses hundreds of nanoparticle formulations on their ability to not just reach a cell, but also how efficiently the nanoparticle can escape with its cargo to reach a cell’s interior.
The test uses mouse cells grown in the laboratory that are genetically engineered to carry a florescent marker called Gal8-mRuby, which shines orange-red when a cellular envelope that engulfs a nanoparticle opens, releasing its cargo into the cell.
Images of the process are then analyzed by a computer program that quickly tracks the nanoparticle location using red fluorescent light and quantifies how effective the nanoparticles are at being released into the cell by assessing the amount of orange-red fluorescent light. , with detailed information about the uptake of the nanoparticles and the delivery of their cargo.
In experiments in mice, Green and his team administered biodegradable nanoparticles carrying mRNA that encoded a gene called luciferase, which makes cells glow. The researchers then tracked whether the mouse cells accepted the gene and began expressing it — lighting up target cells like a lightning bug.
Green’s team found that the top-performing nanoparticles in the cellular tests had a high positive correlation to nanoparticle gene delivery performance in living mice, showing the nanoparticle assay is a good predictor of successful cargo delivery.
In further mouse studies, the researchers discovered that different chemical group combinations in the polymer-based nanoparticles led the nanoparticles to target different tissue types. By analyzing how the particles behaved in the mouse’s body, the researchers found that polymer chemical properties could direct the nanoparticle gene therapy to specific target cells, such as endothelial cells in the lungs or B cells in the spleen.
“By fine-tuning small chemical changes, we can steer a nanoparticle to specific tissues and even specific cells,” said Green. “This would allow us to develop more precisely delivered therapies, which could improve both efficacy and safety.”
Nanoparticle delivery of biological drugs is a growing field, particularly for gene therapies and vaccines.
More from: Johns Hopkins University School of Medicine
The Latest on: Nanoparticle drug delivery
- Exosomes Could Improve Inhaled Therapeuticson August 17, 2022 at 11:00 am
Although commercial manufacturing of exosomes has recently shown extensive improvement, optimization of mRNA loading into exosomes remains a challenge.
- Samsung Biologics, C&T invest in US biotech firm Senda Bioscienceson August 17, 2022 at 12:16 am
By Baek Byung-yeul An investment fund created by Samsung Biologics and Samsung C&T invested $15 million into U.S.-based biotechnology company Senda Biosciences as part of their ef ...
- Flagship Pioneering’s Senda Bio secures $123M for new ‘programmable medicines’on August 16, 2022 at 4:20 pm
Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to a particular destination in the body ...
- US FDA grants orphan drug designation to Privo Technologies’ cisplatin to treat CIS of anterior 2/3 of oral cavityon August 15, 2022 at 11:29 pm
Our novel transmucosal delivery system with embedded cisplatin loaded nanoparticles, PRV111 ... the form and function of the oral cavity,” said Dr. Goldberg. FDA Orphan Drug Designation is granted to ...
- Chinese, U.S. scientists design drug delivery tool for brain canceron August 15, 2022 at 9:45 pm
Chinese and U.S. scientists have proposed a new drug delivery system that can improve immune therapy treatment for brain cancer. This was reported by The ...
- Stimulus-responsive Macromolecules and Nanoparticles for Cancer Drug Deliveryon August 15, 2022 at 5:00 pm
Summary of drug-delivery vehicles and stimulus-responsive ... accumulation of systemically delivered macromolecules and nanoparticles in tumor tissue. Macromolecular carriers and nanoparticle ...
- Engineered Nanoparticles Form Nanoplatform to Target Glioblastomaon August 15, 2022 at 9:48 am
Consequently, PD-1/PD-L1 immune checkpoint blockade is effective in CTL-mediated immune killing. Drug delivery systems based on nanoparticles can overcome the limitations of conventional chemotherapy ...
- Stem Cell Membrane-Coated Nanoparticles in Tumor Therapyon August 8, 2022 at 9:18 am
Cell membrane-coated nanoparticles, applied in targeted drug delivery strategies, combine the intrinsic advantages of synthetic nanoparticles and cell membranes. Although stem cell-based delivery ...
- Nanoparticles – Metal & Metal Oxides Market May See a Big Move | Major Giants Pfizer, Nanobiotix, AstraZenecaon August 4, 2022 at 7:33 am
Targeted Drug Delivery, Proton Therapy, In-vitro Assays & Cell & Phantom Imaging 7) How influencing factors driving the demand of Nanoparticles – Metal & Metal Oxides in next few years?
- How Different Cancer Types Respond to Nanoparticle Drug Deliveryon July 21, 2022 at 5:00 pm
Using nanoparticles to deliver cancer drugs offers a way to ... The findings could help researchers better tailor their drug-delivery particles to specific types of cancer, or design new particles ...
via Bing News
The Latest on: Nanoparticle drug delivery
via Google News